Experimental PET imagingThe limitation of PET imaging for biological adaptive-IMRT assessed in animal models
Section snippets
Animal and tumor model
Seven- to 12-week-old male C3H/HeOuJIco (IFFA Credo Belgium) mice were used for this study. Animals were maintained in a facility approved by the Belgian Ministry of Agriculture in accordance with current regulations and standards. They were housed 4–5 per cage and fed ad libitum. FSA II fibrosarcoma or SCCVII squamous cell carcinoma syngeneic to C3Hf/Kam mice was generated in the right thigh. These tumors were kindly provided by Dr. L. Milas from the University of Texas, M.D. Anderson Cancer
Tumor models
For the 15 mice used in these experiments, the mean tumor volume assessed on MRI images reached 1.65 ± 0.49 ml. In the three different groups, the mean volumes were 1.50 ± 0.49, 1.72 ± 0.39 and 1.86 ± 0.62 ml for the FSAII tumors, SCCVII tumors and FSAII + RX tumors, respectively. Tumor volume was not significantly different between the groups (one-way ANOVA: p = 0.53). The smaller tumor reached 0.92 ml (FSAII group) and the larger tumor reached 2.70 ml (FSAII + RX group).
Voxel-by-voxel analysis
After registration, the tumor was
Discussion
Our study demonstrated that sub-volumes of mouse tumors with high FDG–PET activity, which likely represent the regions where radiation dose might be escalated, poorly matched with the underlying reality assessed by autoradiography (Fig. 3). It was also shown that these results could be extrapolated to human tumors imaged with a whole-body PET camera. Last, it was shown that the use of PET camera with a higher resolution would definitely improve the whole scenario (Fig. 4).
We established that
Acknowledgments
Nicolas Christian is a research fellow of the “Fonds pour la formation à la Recherche dans l’Industrie et l’Agriculture (F.R.I.A.)” of Belgium. The project was supported by a grant from the “Fonds Joseph Maisin”, Brussels, Belgium, by the European Commission’s Sixth Framework Programme funding (Contract N°. LSHC-CT-2004-505785), and by a program project from the “Institut National du Cancer” of France (Project INCa N° RS 020).
References (23)
- et al.
Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II. Clinical results
Int J Radiat Oncol Biol Phys
(2004) - et al.
FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine
Semin Nucl Med
(2007) - et al.
A novel approach to overcome hypoxic tumor resistance. Cu-ATSM-guided intensity-modulated radiation therapy
Int J Radiat Oncol Biol Phys
(2001) - et al.
[F-18]-Fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure
Int J Radiat Oncol Biol Phys
(2006) - et al.
Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer
Int J Radiat Oncol Biol Phys
(2007) - et al.
[18F]Fluoro-deoxy-glucose positron emission tomography ([18F]FDG–PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer
Radiother Oncol
(2006) - et al.
Immobilization device for in vivo and in vitro multimodality image registration of rodent tumors
Radiother Oncol
(2008) The promise of new PET image reconstruction
Phys Med
(2008)- et al.
Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy
Radiother Oncol
(2007) - et al.
The hallmarks of cancer
Cell
(2000)
Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review
Head Neck
Cited by (48)
Research progress of <sup>18</sup>F labeled small molecule positron emission tomography (PET) imaging agents
2020, European Journal of Medicinal ChemistryCitation Excerpt :Although extensive efforts have been made in the field of 18F labeling, the number and types of positron radiopharmaceuticals that can be used for clinical diagnosis are still relatively limited. PET tracers with good chemical stability need to be developed in order to avoid potential defluorination in vivo, ensuring delivery of adequate tracer to the target to allow noninvasive visualization [191]. For the 18F labeling of some PET tracers, the position where 18F was introduced is usually restricted and the newly introduced group must have few effect on the interaction between drug molecules and related target protein.
Dose painting by numbers based on retrospectively determined recurrence probabilities
2017, Radiotherapy and OncologyFunctional imaging in radiation therapy planning for head and neck cancer
2013, Reports of Practical Oncology and RadiotherapySynthesis of new <sup>18</sup>F-radiolabeled silicon-based nitroimidazole compounds
2013, Bioorganic and Medicinal Chemistry